Comparison of ART Outcomes between Two COH Protocols: Gonal-F versus Gonal-F Plus HMG


1. Obstetrics, Gynecology and Infertility Department, Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
2. Epidemiology and Biostatistics Department, Tehran University of Medical Sciences, Tehran, Iran
3. Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: The purpose of this prospective, randomized study was to compare ovarian response as well as oocytes, embryo yields and pregnancy rates in women who underwent ovulation induction for intracytoplasmic sperm injection (ICSI) with recombinant human FSH (rFSH) alone or in combination with human menopausal gonadotropin (HMG).

Materials and Methods: Out of 300 patients in assisted reproductive technique (ART) cycles who underwent down regulation with GnRH analogue in a long protocol, 64 patients received 150 IU/d r FSH until day six when they were randomly allocated into two study groups: group A, who received rFSH alone (n=32) and group B, (n=32) who received rFSH and HMG.

Results: The total number of ampoules of rFSH, the numbers of oocytes retrieved, embryos and serum concentrations of luteinizing hormone (LH) on the day of hCG administration were similar in both treatment groups. However, the numbers of follicles ≥15mm, serum concentrations of progesterone and estradiol on the day of hCG administration were significantly higher in group B when compared to group A. Although the number of high quality embryos (grades A and B) were significantly better in group B, the number of pregnancies and live birth rates were similar in both groups.

Conclusion: The study shows that the addition of LH to rFSH in pituitary – suppressed women undergoing ART improves some parameters of ovarian response, but doesn’t improve overall pregnancy rates.

Keywords: Recombinant, FSH, HMG, Pregnancy Rate, Ovulation Induction

Introduction

Assisted reproductive techniques (ART), most commonly in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), have evolved greatly during the past two decades both in the technical and medical aspects, such as controlled ovarian hyperstimulation (COH). The role of follicle stimulating hormone (FSH) and luteinizing hormone (LH) in ovarian follicular growth and maturation have been known for a long time. Today, it is clear that LH plays a basic role in the final stages of follicle maturity. In response to FSH, the antral follicle reaches a stage in which granulosa cells become sensitive to LH stimulation and LH is capable of influencing both the theca and granulosa cells. This effect depends predominantly on the concentration of LH. Moreover, as LH receptors appear, the dependence of follicular growth and maturation on FSH decreases (1, 2).

Therefore LH may also play a fundamental role in the final maturation of oocytes in ICSI cycles. On the other hand, if follicles are affected by high improper LH concentrations an adverse effect may be seen (3, 4). Studies worldwide have used recombinant LH in order to show its effect on follicular maturation. However since recombinant LH is not currently available in Iran, this study is based on the addition of human menopausal gonadotropin (HMG), with equal content of 75 IU of LH and FSH from the seventh day of ovulation stimulation in order to show the effects of LH on patients treated with human FSH in cycles down-regulated with a GnRH agonist in the long protocol.

Materials and Methods

Patient selection

This controlled, double-blind randomized trial was conducted from June 2006–June 2007 at the Infertil-
ity Department of Vali-e-Asr Hospital as a gynecology resident thesis after being approved by the medical university research committee. From among 300 patients who were in their ART cycles, 64 were chosen and after obtaining written consent they were allocated to one of two groups by simple random sampling, using a random numbers table. Patients, ages 20-35 years with a body mass index (BMI) range of 18-30 Kg/m² were included if they had no underlying medical illnesses and no contraindications for pregnancy. The couples had normal karyotypes with the primary cause of their infertility as either tubal or male factor. Patients diagnosed with polycystic ovarian syndrome (PCOS) and those with FSH levels higher than 12 IU/L were also excluded.

Data collection was done via questionnaires completed by clinic staff and laboratory analyses.

**Study design**

For all patients, baseline FSH and LH values were measured in their previous cycles. All patients underwent pituitary down regulation receiving a once daily subcutaneous dose of 0.2cc Buserelin (Suprefact, Hoechst, AG-Germany), a short-acting GnRH analog from the 21st day of their cycles with oral contraceptive pills (OCP) pretreatment. After ceasing OCP and at least 12 days of pituitary desensitization, all patients received recombinant FSH (Gonal-F, Serono, Switzerland) at a fixed dose of 150 IU/d for the first six days. Thereafter, they were randomly allocated into two groups of 32 patients each.

Group A continued the given dose of treatment if they had 2-3 follicles ≥ 10 mm. On alternating days, patients underwent sonography until they had at least two follicles ≥ 18 mm and at least two other follicles with a diameter > 16 mm when they received 10000 IU hCG. If their response was insufficient, on the seventh day they received 1-2 additional ampoules (75-150 IU) of Gonal-F.

Group B received the same treatment as group A until day seven, when instead of 1-2 ampoules of Gonal-F, they were administered one Gonal-F and one HMG (Merional, IBSA Switzerland). If the response was insufficient, patients received an additional 1-2 ampoules of HMG until at least 2 follicles ≥ 18 mm were observed.

After treatment completion serum progesterone, estradiol and LH levels were measured followed by an intramuscular injection of 10000 IU of hCG. Oocyte pickup was performed 34 to 36 hours following hCG administration. Oocyte maturation was assessed with the criteria described by Veeck (5). After the ICSI procedure, embryos were scored according to the morphologic appearance of their blastomers blastomeres and fragmentation (6). Embryo transfer was performed on day three of ovum pickup with no more than 3 embryos being transferred per patient. In all patients, the luteal phase was supported by Cyclogest (Actover, Alpharma, England) a vaginal progesterone at a dose of 400mg/Bid, which started from the day of oocyte retrieval. In cases where chemical pregnancy was detected two weeks following embryo transfer, clinical pregnancy was confirmed with ultrasound examination six weeks thereafter.

**Statistical analysis**

Results were expressed as mean ± standard deviation. Student’s t test was used to evaluate the differences between both groups. Logistic regression model was used to assess the simultaneous effect of variables on ovary response. P-value <0.05 was considered statistically significant. Data were analyzed using SPSS software version 15.

**Results**

Out of 64 patients in this study who responded to ovulation stimulation, 32 received rFSH alone and 32 received a combination of rFSH and HMG. In total, two patients in each group were excluded from the study and the remainder received ovum pickup and embryo transfer. Both groups had similar demographics and basic characteristics (Table 1).

Table 2 display a comparison of variables between the two groups.

Table 1: Demographic and basic characteristics of patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Group A rFSH (n=30)</th>
<th>Group B rFSH + HMG (n=30)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>27.66 ± 4.3</td>
<td>28.6 ± 3.97</td>
<td>0.387</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.32 ± 3</td>
<td>23.31 ± 4.2</td>
<td>0.415</td>
</tr>
<tr>
<td>Length of infertility (years)</td>
<td>5.75 ± 3.20</td>
<td>6.43 ± 3.40</td>
<td>0.426</td>
</tr>
<tr>
<td>Basic LH (mIU/ml)</td>
<td>1.37 ± 0.28</td>
<td>1.30 ± 0.27</td>
<td>0.366</td>
</tr>
<tr>
<td>Basic FSH (mIU/ml)</td>
<td>5.70 ± 1.47</td>
<td>4.92 ± 1.69</td>
<td>0.065</td>
</tr>
<tr>
<td>Basic Estradiol (pg/ml)</td>
<td>27.56 ± 9.26</td>
<td>29.03 ± 8.77</td>
<td>0.531</td>
</tr>
</tbody>
</table>

*Note: Numbers are Mean ± SD*
In order to assess the simultaneous effect of the variables on ovarian response, a logistic regression model was used. According to the results, on the day of hCG administration, a significant difference between both groups in the serum levels of progesterone (p<0.001) and estradiol (p= 0.037), the number of follicles 15mm (p= 0.040) and number of grade B embryos (p= 0.003) existed.

**Discussion**

The results of this study are in favor of using an exogenous LH supplementation during COH in ART cycles which can be either in the form of rLH or the LH component in HMG. In the present study, patients in group B of the treatment protocol (those who received HMG supplement to provide LH) were superior to group A regarding the number of metaphase II oocytes, levels of LH, progesterone and estradiol on the day of hCG administration in addition to the numbers of grade A and B embryos. However both groups were similar in pregnancy rates and the rate of live births. These findings are close to the results of a systematic review performed by Mochtar et al. (7).

In their study on eleven trials involving 2396 women who had used a GnRH agonist, there was no evidence of a statistical difference in the live birth rate reported in two trials (OR=1.51, 95% CI=(0.79 - 2.87)) and no evidence of a statistical difference in clinical pregnancy rates reported in seven trials (OR=1.15, 95% CI=(0.91 - 1.45)). Successful ART cycles depend both on ovarian stimulation and pituitary suppression in cycles treated by GnRH agonists. GnRH agonists do not cause complete elimination of LH. In order to have the maximum estradiol response, in most cases enough LH levels to occupy less than 1% of LH receptor, can be beneficial. Hence, the residual levels of LH (1-10 IU/d) seems to be able to produce maximum theca cell stimulation (8).

De Placido et al. in their study have shown that the immune reactive LH level is not related to a possible need for LH in the process of a follicular response to ovulation induction. Although there is a relation between immune reactive and bioactive LH, the differences are also notable (10). In the present study, patients were homogenous in their baseline LH levels, nevertheless they responded differently to exogenous LH.

Several other studies conducted in recent years have indicated the positive impact of adding LH in ovarian folliculogenesis. In a study, using a dose of 150 IU of rLH, O’Dea et al. were able to produce a serum LH concentration of 1.2 IU/d, lower concentrations.
of which resulted in decreased success rate of IVF. They also showed that LH has a threshold window (11) and it exerts its beneficial effects in higher levels compared to those which induce atresia in smaller follicles (12).

In another study conducted by researchers at Serono, Swiss company in 1998, a dose of 75 IU/d of rLH was implemented. They observed that on the day of hCG administration, an improvement in follicular maturation as well as increased estradiol and progesterone levels were seen in most cases (13). In our study the hormonal profile showed comparable results.

Nowadays, a number of new protocols including LH have been proposed. There is no doubt about the positive impact of LH on ART cycles, both by improving the quality of oocytes and its positive impact on endometrial receptivity due to higher levels of estrogen (14). Most studies have recommended using LH in poor responders (15) but many others are suggesting it should be also included in protocols for normoresponders (16).

rLH is still not available in many countries. Therefore according to the present work, instead of rLH, starting HMG from the seventh day of stimulation can be a suitable substitute. Finally despite the present knowledge about LH effects, it remains to be elucidated which patients would benefit the most from this practice and therefore more studies are needed to show the importance of LH in ovarian response.

**Conclusion**

Based on our findings, adding LH either as rLH or HMG to FSH in women under pituitary suppression during their ART cycles would most probably result in improvement of a number of ovarian response parameters; however it does not have considerable impact on pregnancy rates.

**Acknowledgements**

The authors wish to thank all academic members and staff at the Vali-e-Asr Reproductive Health Research Center for their sincere cooperation. This article is the result of the postgraduate thesis of Dr. Mandana Saberi. There is no conflict of interest in this article.

**References**